Andrew von Eschenbach has named two people, one of whom should be very familiar to FDA observers, to top positions in the agency. Janet Woodcock, MD, takes a new position, chief medical officer. She will oversee scientific and planning operations. Woodcock has previously been deputy commissioner for operations and director of the agency's drugs and biologics centers. John Dyer, MPH, has been named deputy commissioner for operations and chief operating officer. He will focus on issues concerning management, business processes, and information technology. He was previously COO at CMS, where he helped implement the vast reforms at that agency.